<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>AJMC articles</title><description>AJMC articles</description><link>https://www.ajmc.com/news</link><category>AJMC articles</category><copyright>© 2026 MJH Life Sciences™ and AJMC. All rights reserved.</copyright><lastBuildDate>Fri, 20 Nov 2026 20:44:26 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.ajmc.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>AJMC articles</title><width>144</width><height>47</height><link>https://www.ajmc.com/news</link><url>https://www.ajmc.com/logo.webp</url></image><item><title>&lt;![CDATA[Why Early Therapy Matters in Resistant Gram-Negative Lung Infections]]&gt;</title><link>https://www.ajmc.com/view/why-early-therapy-matters-in-resistant-gram-negative-lung-infections</link><guid isPermaLink="true">https://www.ajmc.com/view/why-early-therapy-matters-in-resistant-gram-negative-lung-infections</guid><description>&lt;![CDATA[Sean Nguyen, PharmD, discusses PROVE data on cefiderocol for resistant respiratory infections and why early, appropriate therapy matters in the ICU.]]&gt;</description><pubDate>Fri, 20 Nov 2026 20:11:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Bridging the Divide: Unveiling an Opportunity for Biosimilar Development]]&gt;</title><link>https://www.ajmc.com/view/bridging-the-divide-unveiling-an-opportunity-for-biosimilar-development</link><guid isPermaLink="true">https://www.ajmc.com/view/bridging-the-divide-unveiling-an-opportunity-for-biosimilar-development</guid><description>&lt;![CDATA[This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.]]&gt;</description><pubDate>Fri, 20 Nov 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Careology Shows How Remote Monitoring Works in 4 Very Different “Rooms”]]&gt;</title><link>https://www.ajmc.com/view/careology-shows-how-remote-monitoring-works-in-4-very-different-rooms-</link><guid isPermaLink="true">https://www.ajmc.com/view/careology-shows-how-remote-monitoring-works-in-4-very-different-rooms-</guid><description>&lt;![CDATA[During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.]]&gt;</description><pubDate>Fri, 20 Nov 2026 16:15:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Reimagine Care Pitches a “Travel Desk” for Patients Between Cancer Visits]]&gt;</title><link>https://www.ajmc.com/view/reimagine-care-pitches-a-travel-desk-for-patients-between-cancer-visits</link><guid isPermaLink="true">https://www.ajmc.com/view/reimagine-care-pitches-a-travel-desk-for-patients-between-cancer-visits</guid><description>&lt;![CDATA[John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.]]&gt;</description><pubDate>Fri, 20 Nov 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Anemia, Iron Deficiency Tied to Acute Heart Failure in Pregnancy]]&gt;</title><link>https://www.ajmc.com/view/anemia-iron-deficiency-tied-to-acute-heart-failure-in-pregnancy</link><guid isPermaLink="true">https://www.ajmc.com/view/anemia-iron-deficiency-tied-to-acute-heart-failure-in-pregnancy</guid><description>&lt;![CDATA[Anemia and iron deficiency are linked to higher odds of acute heart failure during pregnancy and after childbirth, according to a study.]]&gt;</description><pubDate>Fri, 20 Nov 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Caregiving Cuts Across Party Lines: Sen Andy Kim]]&gt;</title><link>https://www.ajmc.com/view/caregiving-cuts-across-party-lines-sen-andy-kim</link><guid isPermaLink="true">https://www.ajmc.com/view/caregiving-cuts-across-party-lines-sen-andy-kim</guid><description>&lt;![CDATA[Senator Andy Kim (D, New Jersey) discusses the response to a Senate speech on caregiving and disagreements over how to support caregivers.]]&gt;</description><pubDate>Fri, 20 Nov 2026 14:43:19 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Beyond Traditional Metrics: Rethinking Access and the Unseen Impact of eConsults]]&gt;</title><link>https://www.ajmc.com/view/beyond-traditional-metrics-rethinking-access-and-the-unseen-impact-of-econsults</link><guid isPermaLink="true">https://www.ajmc.com/view/beyond-traditional-metrics-rethinking-access-and-the-unseen-impact-of-econsults</guid><description>&lt;![CDATA[This commentary highlights limitations of traditional access metrics and proposes incorporating eConsults to better capture specialty capacity, workload, and performance in modern health care delivery.]]&gt;</description><pubDate>Fri, 20 Nov 2026 14:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[AJMC® in the Press, November 20, 2026]]&gt;</title><link>https://www.ajmc.com/view/ajmc-in-the-press-november-20-2026</link><guid isPermaLink="true">https://www.ajmc.com/view/ajmc-in-the-press-november-20-2026</guid><description>&lt;![CDATA[Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.]]&gt;</description><pubDate>Fri, 20 Nov 2026 14:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Late-Stage Alzheimer&apos;s Disease: Individualized Caregiving and Caregiver Support]]&gt;</title><link>https://www.ajmc.com/view/late-stage-alzheimer-s-disease-individualized-caregiving-and-caregiver-support</link><guid isPermaLink="true">https://www.ajmc.com/view/late-stage-alzheimer-s-disease-individualized-caregiving-and-caregiver-support</guid><description>&lt;![CDATA[Every dementia journey differs, and so must the care plan. Effective late-stage care coordinates education, comorbidity management, and behavioral strategies in a way that works for patients and caregivers alike.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[MS Treatment Guidelines and Payer Step Therapy: Finding Balance]]&gt;</title><link>https://www.ajmc.com/view/ms-treatment-guidelines-and-payer-step-therapy-finding-balance</link><guid isPermaLink="true">https://www.ajmc.com/view/ms-treatment-guidelines-and-payer-step-therapy-finding-balance</guid><description>&lt;![CDATA[Existing MS guidelines are outdated and rarely used, while payers seek algorithms that individualized care cannot supply. The panel argues that early access to high-efficacy therapy should be a guiding principle.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[The One Bronchiectasis Model: Treating Beyond the Underlying Cause]]&gt;</title><link>https://www.ajmc.com/view/the-one-bronchiectasis-model-treating-beyond-the-underlying-cause</link><guid isPermaLink="true">https://www.ajmc.com/view/the-one-bronchiectasis-model-treating-beyond-the-underlying-cause</guid><description>&lt;![CDATA[Different causes of bronchiectasis may start differently, but Dr. Patrick Flume argues their downstream disease looks similar enough that therapies developed for one etiology can benefit many others.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Adoption, Payer Priorities, and What&apos;s Next in EGFR Exon 20 NSCLC]]&gt;</title><link>https://www.ajmc.com/view/adoption-payer-priorities-and-what-s-next-in-egfr-exon-20-nsclc</link><guid isPermaLink="true">https://www.ajmc.com/view/adoption-payer-priorities-and-what-s-next-in-egfr-exon-20-nsclc</guid><description>&lt;![CDATA[Cost, route of administration, tolerability, and care team experience all shape adoption, while anticipated approvals of oral options point toward a more crowded first-line landscape.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice]]&gt;</title><link>https://www.ajmc.com/view/defining-high-efficacy-ms-therapy-access-formularies-and-patient-choice</link><guid isPermaLink="true">https://www.ajmc.com/view/defining-high-efficacy-ms-therapy-access-formularies-and-patient-choice</guid><description>&lt;![CDATA[High efficacy has no single definition, and a large toolbox means little when formularies limit access. The panel describes how patient preference, route of administration, and payer constraints shape real decisions.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Alzheimer&apos;s Disease Treatment Selection: Anti-Amyloid Uptake and Stage-Based Care]]&gt;</title><link>https://www.ajmc.com/view/alzheimer-s-disease-treatment-selection-anti-amyloid-uptake-and-stage-based-care</link><guid isPermaLink="true">https://www.ajmc.com/view/alzheimer-s-disease-treatment-selection-anti-amyloid-uptake-and-stage-based-care</guid><description>&lt;![CDATA[Population prevalence, treatment hesitancy, and modest slowing of decline shape who receives anti-amyloid therapy today. Management differs sharply across the six stages, from clinical trials and lifestyle changes to comprehensive caregiver-centered care.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Reducing Bronchiectasis Mortality: Treatment Advances and What&apos;s Next]]&gt;</title><link>https://www.ajmc.com/view/reducing-bronchiectasis-mortality-treatment-advances-and-what-s-next</link><guid isPermaLink="true">https://www.ajmc.com/view/reducing-bronchiectasis-mortality-treatment-advances-and-what-s-next</guid><description>&lt;![CDATA[With a first-in-class treatment now available and awareness slowly spreading, the field sees a genuine opportunity to change bronchiectasis morbidity and mortality over the next decade.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Cystatin C, Creatinine eGFR Gap Flags Higher Mortality, HF Risk]]&gt;</title><link>https://www.ajmc.com/view/cystatin-c-creatinine-egfr-gap-flags-higher-mortality-hf-risk</link><guid isPermaLink="true">https://www.ajmc.com/view/cystatin-c-creatinine-egfr-gap-flags-higher-mortality-hf-risk</guid><description>&lt;![CDATA[Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.]]&gt;</description><pubDate>Thu, 19 Nov 2026 21:32:44 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Owning the Medication List Across Care Transitions]]&gt;</title><link>https://www.ajmc.com/view/owning-the-medication-list-across-care-transitions</link><guid isPermaLink="true">https://www.ajmc.com/view/owning-the-medication-list-across-care-transitions</guid><description>&lt;![CDATA[Rita Shane, PharmD, of Cedars-Sinai joins Mark Makhinson, PharmD, MBA, to discuss medication safety, care transitions, and AI in pharmacy.]]&gt;</description><pubDate>Thu, 19 Nov 2026 21:01:29 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Cefiderocol Holds Activity Against Resistant Pseudomonas in VAP]]&gt;</title><link>https://www.ajmc.com/view/cefiderocol-holds-activity-against-resistant-pseudomonas-in-vap</link><guid isPermaLink="true">https://www.ajmc.com/view/cefiderocol-holds-activity-against-resistant-pseudomonas-in-vap</guid><description>&lt;![CDATA[Sean Nguyen, PharmD, discusses SENTRY data showing cefiderocol activity against resistant Pseudomonas VAP isolates and what it means for ICU care.]]&gt;</description><pubDate>Thu, 19 Nov 2026 19:04:10 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say]]&gt;</title><link>https://www.ajmc.com/view/iron-deficiency-in-heart-failure-is-a-workflow-problem-faculty-say</link><guid isPermaLink="true">https://www.ajmc.com/view/iron-deficiency-in-heart-failure-is-a-workflow-problem-faculty-say</guid><description>&lt;![CDATA[Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.]]&gt;</description><pubDate>Thu, 19 Nov 2026 18:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis]]&gt;</title><link>https://www.ajmc.com/view/fda-approves-first-sirna-therapy-for-achr-positive-myasthenia-gravis</link><guid isPermaLink="true">https://www.ajmc.com/view/fda-approves-first-sirna-therapy-for-achr-positive-myasthenia-gravis</guid><description>&lt;![CDATA[The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.]]&gt;</description><pubDate>Thu, 19 Nov 2026 16:57:30 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Local vs Central Testing: What It Means for Ensitrelvir COVID-19 PEP]]&gt;</title><link>https://www.ajmc.com/view/local-vs-central-testing-what-it-means-for-ensitrelvir-covid-19-pep</link><guid isPermaLink="true">https://www.ajmc.com/view/local-vs-central-testing-what-it-means-for-ensitrelvir-covid-19-pep</guid><description>&lt;![CDATA[Florin Draica, MD, MBA, of Shionogi on ensitrelvir PEP outcomes in patients infected at baseline despite negative antigen tests.]]&gt;</description><pubDate>Thu, 19 Nov 2026 16:57:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic]]&gt;</title><link>https://www.ajmc.com/view/most-patients-with-psoriasis-screened-positive-for-psa-at-one-dermatology-clinic</link><guid isPermaLink="true">https://www.ajmc.com/view/most-patients-with-psoriasis-screened-positive-for-psa-at-one-dermatology-clinic</guid><description>&lt;![CDATA[In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.]]&gt;</description><pubDate>Thu, 19 Nov 2026 16:45:36 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Obesity Care Ownership Shifts to Specialties That Win Coverage]]&gt;</title><link>https://www.ajmc.com/view/obesity-care-ownership-shifts-to-specialties-that-win-coverage</link><guid isPermaLink="true">https://www.ajmc.com/view/obesity-care-ownership-shifts-to-specialties-that-win-coverage</guid><description>&lt;![CDATA[Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.]]&gt;</description><pubDate>Thu, 19 Nov 2026 15:54:42 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[New Employer Guide Maps Diabetes Prevention, Care Resources]]&gt;</title><link>https://www.ajmc.com/view/new-employer-guide-maps-diabetes-prevention-care-resources</link><guid isPermaLink="true">https://www.ajmc.com/view/new-employer-guide-maps-diabetes-prevention-care-resources</guid><description>&lt;![CDATA[An employer coalition&apos;s new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.]]&gt;</description><pubDate>Thu, 19 Nov 2026 15:28:44 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Transitioning to All-Oral AML Therapy: Prior Authorization Pearls and Copay Timing]]&gt;</title><link>https://www.ajmc.com/view/transitioning-to-all-oral-aml-therapy-prior-authorization-pearls-and-copay-timing</link><guid isPermaLink="true">https://www.ajmc.com/view/transitioning-to-all-oral-aml-therapy-prior-authorization-pearls-and-copay-timing</guid><description>&lt;![CDATA[Starting prior authorization before treatment begins, anticipating end-of-year deductible resets, and persisting through appeals can determine whether patients transition smoothly to oral AML therapy.]]&gt;</description><pubDate>Thu, 19 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Securing Access to Oral AML Therapy: Formularies, Prior Authorization, and Copays]]&gt;</title><link>https://www.ajmc.com/view/securing-access-to-oral-aml-therapy-formularies-prior-authorization-and-copays</link><guid isPermaLink="true">https://www.ajmc.com/view/securing-access-to-oral-aml-therapy-formularies-prior-authorization-and-copays</guid><description>&lt;![CDATA[Adding oral agents to hospital formularies speeds initiation but creates financial risk, and even dedicated access teams struggle against prior authorization delays, steep copays, and automated denials.]]&gt;</description><pubDate>Thu, 19 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Ensitrelvir PEP Lowers Viral Load in COVID-19 Breakthrough Infections]]&gt;</title><link>https://www.ajmc.com/view/ensitrelvir-pep-lowers-viral-load-in-covid-19-breakthrough-infections</link><guid isPermaLink="true">https://www.ajmc.com/view/ensitrelvir-pep-lowers-viral-load-in-covid-19-breakthrough-infections</guid><description>&lt;![CDATA[In a Q&amp;amp;A, Florin Draica, MD, MBA, explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to prioritize.]]&gt;</description><pubDate>Wed, 18 Nov 2026 22:08:38 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Camden Residents Weigh In on Psychedelic Therapy: Jeff Brown]]&gt;</title><link>https://www.ajmc.com/view/camden-residents-weigh-in-on-psychedelic-therapy-jeff-brown</link><guid isPermaLink="true">https://www.ajmc.com/view/camden-residents-weigh-in-on-psychedelic-therapy-jeff-brown</guid><description>&lt;![CDATA[Jeff Brown of the Camden Coalition says community input should guide psychedelic-assisted therapy rollout, including Medicaid access and safety.]]&gt;</description><pubDate>Wed, 18 Nov 2026 21:52:22 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Low CRC Incidence Found After Endoscopic Mucosal Resection]]&gt;</title><link>https://www.ajmc.com/view/low-crc-incidence-found-after-endoscopic-mucosal-resection</link><guid isPermaLink="true">https://www.ajmc.com/view/low-crc-incidence-found-after-endoscopic-mucosal-resection</guid><description>&lt;![CDATA[CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.]]&gt;</description><pubDate>Wed, 18 Nov 2026 21:10:21 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[FDA Approves Obinutuzumab as First Therapy for Membranous Nephropathy]]&gt;</title><link>https://www.ajmc.com/view/fda-approves-obinutuzumab-as-first-therapy-for-membranous-nephropathy</link><guid isPermaLink="true">https://www.ajmc.com/view/fda-approves-obinutuzumab-as-first-therapy-for-membranous-nephropathy</guid><description>&lt;![CDATA[Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.]]&gt;</description><pubDate>Wed, 18 Nov 2026 21:07:57 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item></channel></rss>